Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breast Tumors from the NCCTG (Alliance) N9831 Trial
      QxMD      Google Scholar   
Citation:
J Natl Cancer Inst vol 109 (2)
Year:
2016
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
ppub
Note:
These studies were supported in part by grants from the National Cancer Institute (CA129949), the Breast Cancer Research Foundation, and the 26.2 with Donna Foundation. Additional support for infrastructure was derived from the Mayo Clinic Comprehensive Cancer Center support grant CA15083 and the Mayo Foundation.
Methodological:
No
Biospecimen:
Yes
SDC:
No
Book Volume:
6
Parents:
2374  
Children:
None
Program:
OGC
Primary Committee:
Breast
Sec. Committees:
   
Pharmas:
 
Grants:
U10CA180821, U24CA196171  
Corr. Author:
 
Authors:
                           
Networks:
LAPS-MN026, LAPS-NC007, PR028   
Study
NCCTG-N9831
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords: